Hepato-biliary late effects in survivors of childhood and adolescent cancer

A report from the Children's Oncology Group

Sharon Castellino, Andrew Muir, Ami Shah, Sheila Shope, Kevin McMullen, Kathy Ruble, Ashley Barber, Andrew Davidoff, Melissa M. Hudson

Research output: Contribution to journalArticle

Abstract

Curative therapy for childhood and adolescent cancer translates to 1 in 640 young adults being a survivor of cancer. Although acute hepato-biliary toxicity occurs commonly during pediatric cancer therapy, the impact of antineoplastic therapy on long-term liver health in childhood/adolescent cancer survivors is unknown. This article reviews the medical literature on late liver dysfunction following treatment for childhood/adolescent cancer. We also outline the Children's Oncology Group (COG) guidelines for screening and follow-up of hepato-biliary sequelae. As the population of survivors grow and age, vigilance for risks to hepatic health needs to continue based on specific exposures during curative cancer therapy.

Original languageEnglish (US)
Pages (from-to)663-669
Number of pages7
JournalPediatric Blood and Cancer
Volume54
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Neoplasms
Therapeutics
Liver
Health
Antineoplastic Agents
Liver Diseases
Young Adult
Guidelines
Pediatrics
Population

Keywords

  • Adolescent cancer survivor
  • Childhood cancer
  • Hepato-biliary late effects
  • Screening

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)

Cite this

Hepato-biliary late effects in survivors of childhood and adolescent cancer : A report from the Children's Oncology Group. / Castellino, Sharon; Muir, Andrew; Shah, Ami; Shope, Sheila; McMullen, Kevin; Ruble, Kathy; Barber, Ashley; Davidoff, Andrew; Hudson, Melissa M.

In: Pediatric Blood and Cancer, Vol. 54, No. 5, 05.2010, p. 663-669.

Research output: Contribution to journalArticle

Castellino, S, Muir, A, Shah, A, Shope, S, McMullen, K, Ruble, K, Barber, A, Davidoff, A & Hudson, MM 2010, 'Hepato-biliary late effects in survivors of childhood and adolescent cancer: A report from the Children's Oncology Group', Pediatric Blood and Cancer, vol. 54, no. 5, pp. 663-669. https://doi.org/10.1002/pbc.22265
Castellino, Sharon ; Muir, Andrew ; Shah, Ami ; Shope, Sheila ; McMullen, Kevin ; Ruble, Kathy ; Barber, Ashley ; Davidoff, Andrew ; Hudson, Melissa M. / Hepato-biliary late effects in survivors of childhood and adolescent cancer : A report from the Children's Oncology Group. In: Pediatric Blood and Cancer. 2010 ; Vol. 54, No. 5. pp. 663-669.
@article{5f06edbc8e3342adb7981c62f24daa6d,
title = "Hepato-biliary late effects in survivors of childhood and adolescent cancer: A report from the Children's Oncology Group",
abstract = "Curative therapy for childhood and adolescent cancer translates to 1 in 640 young adults being a survivor of cancer. Although acute hepato-biliary toxicity occurs commonly during pediatric cancer therapy, the impact of antineoplastic therapy on long-term liver health in childhood/adolescent cancer survivors is unknown. This article reviews the medical literature on late liver dysfunction following treatment for childhood/adolescent cancer. We also outline the Children's Oncology Group (COG) guidelines for screening and follow-up of hepato-biliary sequelae. As the population of survivors grow and age, vigilance for risks to hepatic health needs to continue based on specific exposures during curative cancer therapy.",
keywords = "Adolescent cancer survivor, Childhood cancer, Hepato-biliary late effects, Screening",
author = "Sharon Castellino and Andrew Muir and Ami Shah and Sheila Shope and Kevin McMullen and Kathy Ruble and Ashley Barber and Andrew Davidoff and Hudson, {Melissa M.}",
year = "2010",
month = "5",
doi = "10.1002/pbc.22265",
language = "English (US)",
volume = "54",
pages = "663--669",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Hepato-biliary late effects in survivors of childhood and adolescent cancer

T2 - A report from the Children's Oncology Group

AU - Castellino, Sharon

AU - Muir, Andrew

AU - Shah, Ami

AU - Shope, Sheila

AU - McMullen, Kevin

AU - Ruble, Kathy

AU - Barber, Ashley

AU - Davidoff, Andrew

AU - Hudson, Melissa M.

PY - 2010/5

Y1 - 2010/5

N2 - Curative therapy for childhood and adolescent cancer translates to 1 in 640 young adults being a survivor of cancer. Although acute hepato-biliary toxicity occurs commonly during pediatric cancer therapy, the impact of antineoplastic therapy on long-term liver health in childhood/adolescent cancer survivors is unknown. This article reviews the medical literature on late liver dysfunction following treatment for childhood/adolescent cancer. We also outline the Children's Oncology Group (COG) guidelines for screening and follow-up of hepato-biliary sequelae. As the population of survivors grow and age, vigilance for risks to hepatic health needs to continue based on specific exposures during curative cancer therapy.

AB - Curative therapy for childhood and adolescent cancer translates to 1 in 640 young adults being a survivor of cancer. Although acute hepato-biliary toxicity occurs commonly during pediatric cancer therapy, the impact of antineoplastic therapy on long-term liver health in childhood/adolescent cancer survivors is unknown. This article reviews the medical literature on late liver dysfunction following treatment for childhood/adolescent cancer. We also outline the Children's Oncology Group (COG) guidelines for screening and follow-up of hepato-biliary sequelae. As the population of survivors grow and age, vigilance for risks to hepatic health needs to continue based on specific exposures during curative cancer therapy.

KW - Adolescent cancer survivor

KW - Childhood cancer

KW - Hepato-biliary late effects

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=77950514641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950514641&partnerID=8YFLogxK

U2 - 10.1002/pbc.22265

DO - 10.1002/pbc.22265

M3 - Article

VL - 54

SP - 663

EP - 669

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -